New hope for young bone cancer patients? drug tested in relapse
NCT ID NCT03006848
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This study tested a drug called avelumab in 19 children and young adults (ages 12-49) whose osteosarcoma (a type of bone cancer) had come back or was not responding to standard treatments. The goal was to see if avelumab could shrink tumors or stop the cancer from growing for at least 16 weeks. Researchers also monitored side effects and quality of life. The drug works by helping the immune system attack cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
St Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
Texas Children's Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill stall advanced sarcomas?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Experimental vaccine fights sarcoma with Patient's own immune cells
- New drug hope for rare sarcomas after chemo fails
- Dietary change explored as cancer support strategy